Sargent Bickham Lagudis LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 149 filers reported holding DENALI THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.

Quarter-by-quarter ownership
Sargent Bickham Lagudis LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$8,000
-38.5%
1650.0%0.00%0.0%
Q2 2021$13,000
+44.4%
1650.0%0.00%0.0%
Q1 2021$9,000
-60.9%
165
-50.0%
0.00%0.0%
Q4 2020$23,000
+283.3%
330
+100.0%
0.00%0.0%
Q3 2020$6,000
+20.0%
165
-11.8%
0.00%0.0%
Q2 2020$5,0001870.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$404,042,00054.41%
Bratton Capital Management, L.P. 953,035$19,785,00029.05%
Flagship Pioneering Inc. 8,005,747$166,199,0007.19%
Casdin Capital, LLC 400,000$8,304,000,0000.78%
Temasek Holdings (Private) Ltd 4,410,457$91,561,0000.65%
IRONWOOD INVESTMENT MANAGEMENT LLC 22,595$469,0000.37%
MARK ASSET MANAGEMENT LP 70,532$1,464,0000.34%
Artal Group S.A. 400,000$8,304,0000.34%
PIER 88 INVESTMENT PARTNERS LLC 27,650$574,0000.24%
WASATCH ADVISORS LP 996,147$20,680,0000.20%
View complete list of DENALI THERAPEUTICS INC shareholders